based on the assumption that increased search queries for itch, and thus interest, serves as a proxy of increased itch symptoms in the public. That SVI for pain did not correlate with temperature further validates our observations for itch.
Combined epidermal and follicular cell suspension as a novel surgical approach for acral vitiligo To the Editor: Autologous noncultured epidermal cell suspension (ECS) and follicular cell suspension (FCS) are effective modalities for the surgical management of stable vitiligo. There is need for further modification of these methods as repigmentation over acral and bony areas is not satisfactory with these methods. We devised a new surgical approach by combining ECS and FCS.
We followed the method described in our previous publication 1 for preparing and transplanting ECS and FCS. ECS was mixed with FCS in a 1:5 ratio. The combined suspension was transplanted to the dermabraded vitiligo patches. No additional treatment apart from regular sun exposure was advised.
In this case series, 5 patients with 12 symmetric vitiligo patches underwent combined ECS and FCS on one side and ECS on the opposite side. All except 1 patient had acral, bony, or nonsegmental vitiligo patches (Table I) . Lesions were of comparable sizes with lesional stability of more than 1 year. They were followed up at 4-, 8-, and 16-week intervals by a blinded observer and the extent of repigmentation (by visual assessment and computerized image analysis) (Fig 1) , color match, patient global assessment score, and complications were noted.
Extent of repigmentation at week 16 by visual assessment was superior in combined ECS and FCS as compared with ECS whether attaining 75% or greater (7/7, 100% vs 4/5, 80%) or 90% or greater repigmentation (7/7, 100% vs 1/5, 20%) ( Table I) . Similar results were obtained on computerized image analysis: combined ECS and It is known that keratinocytes supply essential growth factors for melanocyte growth and proliferation. 3 ECS was chosen as a control in this study because it is the established surgical modality with a good outcome and hence we could compare any added benefit of our novel approach. The superior repigmentation obtained in combined ECS and FCS (Fig 1) might be a result of keratinocyte growth factors like stem cell factor or basic fibroblast growth factor from ECS, which facilitates the growth of various stem cells in FCS. It was shown in a mouse study that stem cell factor and basic fibroblast growth factor should be supplied in the culture medium for the in vitro proliferation of melanocyte stem cells. 4 This new approach may be a good option in acral vitiligo where melanocyte stem cell defect is one of the reasons for treatment resistance.
Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: A series of 15 cases To the Editor: Treatment of papulopustular rosacea (PPR) and periorificial dermatitis (POD) can be challenging in children. Demodex mites, although part of the normal-appearing skin fauna, are more numerous in rosacea and POD than in normal-appearing skin. 1 In 2014, we reported a case of severe oculocutaneous rosacea in a 12-year-old girl treated with a single dose of oral ivermectin 2 ; the excellent response encouraged us to use it in subsequent cases.
The aim of this retrospective study was to assess the benefit and tolerability of oral and topical ivermectin therapy in pediatric PPR and POD.
Eight patients with PPR and 7 with POD (mean age 9.8 6 2.2 years) were treated with either a single dose of 200 to 250 g/kg of oral ivermectin or a compound of 1% ivermectin in an oil-inwater base cream applied once a day for 3 months. Oral ivermectin was prescribed for 6 children with PPR and 3 with POD. Oral or topical therapy was chosen depending on the severity of the condition. No other medications were allowed.
To assess disease severity at baseline and after treatment, we applied the Investigator Global Assessment score by retrospectively reviewing clinical charts and photographs. We rated overall severity on a 0-to-4 scale as 0 ¼ clear, 1 ¼ almost clear, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ severe. We considered treatment to be successful when lesions cleared or almost cleared. Recurrence was documented when a disease flare required a further course of therapy. Table I summarizes the demographic and clinical data.
Complete or almost complete clearance (Investigator Global Assessment score 0-1) was achieved in 8 patients treated orally and in 6 children treated with topical ivermectin. One patient did not improve after oral therapy. The overall response to topical or oral ivermectin was excellent: 14 of 15 (93%) patients achieved complete or almost complete clearance of lesions (Fig 1) ; 3 of 14 patients experienced relapses (21%) and 11 of 14 remained disease-free for a prolonged period. Mean follow-up was 11.9 6 7.1 (range 2-42) months. The only adverse event observed was mild, transient desquamation of the affected skin in 3 patients receiving oral ivermectin and in 2 patients using topical ivermectin.
In 2014, the US Food and Drug Administration approved 1% ivermectin cream for treatment of rosacea in adults. Oral ivermectin is licensed for treatment of filariasis in children weighing more than 15 kg and has been used off-label in refractory cases of rosacea. 2, 3 Topical ivermectin may produce a burning sensation, pruritus, and dry skin in 0.7% to 1.8% of patients. 4 The only adverse event in our series was transient, mild desquamation in 5 patients. This was observed in patients receiving either topical or oral therapy. We hypothesize the desquamation may be a result of a Mazzotti-like reaction resulting from an immunologic reaction to dying mites, as observed in systemic parasitoses after ivermectin therapy. 5 
